🟠 Recent analyst ratings include Chardan Capital lowering its price target from $17.00 to $15.00 and HC Wainwright reiterating a $10.00 target with a "Buy" rating. 
#CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA